InsideArbitrage Event Driven Monitor – February 23, 2026

Why It Matters

These updates signal accelerating deal momentum across media, biotech, and energy sectors, while heightened shareholder activism and aggressive capital return strategies reshape valuation dynamics for investors.

Key Takeaways

• Paramount clears HSR waiting period for Warner Bros. deal
• FTC terminates waiting period for Amicus Therapeutics acquisition
• Exact Sciences shareholders approve Abbott acquisition, closing Q2
• Blackstone Infrastructure receives FERC approval for TXNM purchase
• Nucor launches $4 billion buyback, 10% market cap

Pulse Analysis

Regulatory clearances are accelerating high‑profile mergers, as seen with Paramount’s successful navigation of the Hart‑Scott‑Rodino waiting period and foreign approval for the Warner Bros. Discovery acquisition. Such milestones reduce uncertainty for investors, potentially narrowing spreads in merger arbitrage strategies and prompting a re‑pricing of related equities. The FTC’s early termination of the waiting period for Amicus Therapeutics further illustrates a trend toward faster antitrust resolutions in the biotech space, encouraging capital flows into pending consolidations.

Shareholder activism is gaining traction, highlighted by Braeden Lichti’s push for a strategic review at enVVeno Medical and Parex Resources’ slate of director nominations at GeoPark. Simultaneously, activist investor Ed Garden’s stake in Fortune Brands Innovations underscores a growing appetite for board influence to drive operational turnarounds. Insider buying across MSCI, Arrow Electronics, and Blackstone signals confidence from executives, often serving as a bellwether for market sentiment and reinforcing the credibility of ongoing strategic initiatives.

Capital allocation decisions are reshaping balance sheets, with Nucor’s $4 billion share‑repurchase plan representing roughly 10% of its market cap, while Manulife and Fidelis Insurance also expanded buyback programs. These moves aim to return excess cash to shareholders, support earnings per share growth, and signal management’s belief that current valuations are attractive. Coupled with a wave of C‑suite transitions—from new CFO appointments at Nucor to retirements at Choice Hotels—companies are positioning leadership teams to execute these financial strategies effectively, influencing both short‑term stock performance and long‑term strategic direction.